Fundraising Fox
/People
Sign in

Kevin Bitterman

Investor

Partner at Atlas Venture

Cambridge, Massachusetts

Writes $10M – $50M checks · typically $25M

Find your path to Kevin

Sign up to see every warm intro you have to Kevin

  • Paths you didn't know you had: your email and LinkedIn already hold routes to Kevin. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

About

Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.

Contact· self-published, not guessed

Invests in

Biotech

Deals · 9

Renasant BioBoard seat

via Atlas Venture · filed Jul 2025 · $30M raise

GrobioBoard seat

via Atlas Venture · filed Jul 2024 · $60.4M raise

Chroma MedicineBoard seat

via Atlas Venture · filed Sep 2023 · $135M raise

Navitor PharmaceuticalsBoard seat

via Atlas Venture · filed May 2020 · $20.2M raise

Akero Therapeutics, Inc.Board seat

via Atlas Venture · filed Dec 2018 · $45.5M raise

Morphic Holding, Inc.Board seat

via Atlas Venture · filed Jul 2016 · $51.5M raise

KALA BIOBoard seat

via Atlas Venture · filed Aug 2015 · $7M raise

Direct Vet MarketingBoard seat

via Atlas Venture · filed Jul 2015 · $52.3M raise

NeuroneticsBoard seat

via Atlas Venture · filed May 2015 · $34.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Investor

Akero TherapeuticsArsenal MedicalBiolex TherapeuticsCurie TherapeuticsDisc MedicineFollicaGenocea BiosciencesGRO BiosciencesJudo BioMariana OncologyMorphic TherapeuticPulmatrixRemix TherapeuticsVets First ChoiceVisterra

Sources: the firm's website · SEC Form D filings · curated public sources.

Colleagues at Atlas Venture

Aimee Raleigh
Principal at Atlas Venture
Akshay Vaishnaw
Venture Partner at Atlas Venture
Alex Harding
Entrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo at Atlas Venture
Alex Lugovskoy
Atlas Advisor; Chief Executive Officer, Diagonal Therapeutics at Atlas Venture
Alfica Sehgal
Entrepreneur-in-Residence; Chief Scientific Officer, Judo Bio at Atlas Venture
Andrea DiMella
Senior Vice President, Head of Talent at Atlas Venture
Angela Lam
Executive Assistant at Atlas Venture
Bruce Booth
Partner at Atlas Venture

Network1

Dave Maki
Managing Partner at Altitude Ventures Management, Llc

Investors connected to Kevin in public investor directories — a warm-intro map.

Frequently asked questions

Who is Kevin Bitterman?
Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.
Where does Kevin Bitterman work?
Kevin Bitterman is Partner at Atlas Venture.
What does Kevin Bitterman invest in?
Kevin Bitterman invests in Biotech.
What check size does Kevin Bitterman write?
Kevin Bitterman typically writes checks of $10M – $50M.
What boards does Kevin Bitterman sit on?
Kevin Bitterman holds tracked board seats at Akero Therapeutics, Akero Therapeutics, Inc., Chroma Medicine, Direct Vet Marketing, Disc Medicine, Editas Medicine, Grobio, Judo Bio, KALA BIO, Kinaset Therapeutics.
What companies has Kevin Bitterman invested in?
Investments tracked here include Akero Therapeutics, Arsenal Medical, Biolex Therapeutics, Curie Therapeutics, Disc Medicine, Follica, Genocea Biosciences, GRO Biosciences, Judo Bio, KALA BIO, Mariana Oncology, Morphic Therapeutic, and 6 more.

Founder mafias

About this profile. Compiled from public sources — Atlas Venture's own website, regulatory filings and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights